Fifth Third Bancorp grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 18.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,535 shares of the company’s stock after purchasing an additional 2,076 shares during the quarter. Fifth Third Bancorp’s holdings in IDEXX Laboratories were worth $6,769,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also modified their holdings of IDXX. Altshuler Shaham Ltd bought a new position in IDEXX Laboratories in the 4th quarter worth $26,000. Resurgent Financial Advisors LLC bought a new position in IDEXX Laboratories in the 4th quarter worth $31,000. Pacifica Partners Inc. bought a new position in IDEXX Laboratories in the 1st quarter worth $33,000. Carolinas Wealth Consulting LLC bought a new position in IDEXX Laboratories in the 1st quarter worth $39,000. Finally, Fortis Capital Advisors LLC bought a new position in IDEXX Laboratories in the 4th quarter worth $41,000. Institutional investors own 86.53% of the company’s stock.
IDEXX Laboratories Price Performance
NASDAQ:IDXX opened at $498.01 on Friday. The firm has a market cap of $41.29 billion, a PE ratio of 59.93, a price-to-earnings-growth ratio of 2.95 and a beta of 1.19. IDEXX Laboratories, Inc. has a 12 month low of $317.06 and a 12 month high of $515.79. The company has a quick ratio of 0.71, a current ratio of 1.08 and a debt-to-equity ratio of 0.83. The company’s 50-day moving average price is $478.62 and its two-hundred day moving average price is $475.01.
Analyst Ratings Changes
Several analysts have issued reports on IDXX shares. Morgan Stanley raised their price target on shares of IDEXX Laboratories from $543.00 to $590.00 and gave the stock an “overweight” rating in a research report on Thursday, March 23rd. StockNews.com began coverage on shares of IDEXX Laboratories in a research report on Thursday, May 18th. They issued a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $527.86.
Insiders Place Their Bets
In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 2,187 shares of the business’s stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $469.02, for a total value of $1,025,746.74. Following the completion of the transaction, the director now directly owns 872 shares of the company’s stock, valued at $408,985.44. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, Director Jonathan W. Ayers sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $489.23, for a total transaction of $4,892,300.00. Following the completion of the sale, the director now directly owns 137,039 shares of the company’s stock, valued at $67,043,589.97. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Sophie V. Vandebroek sold 2,187 shares of the business’s stock in a transaction that occurred on Thursday, May 4th. The stock was sold at an average price of $469.02, for a total transaction of $1,025,746.74. Following the sale, the director now directly owns 872 shares of the company’s stock, valued at $408,985.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 13,187 shares of company stock valued at $6,402,047. Insiders own 2.11% of the company’s stock.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Read More
- Five stocks we like better than IDEXX Laboratories
- MarketBeat Week in Review – 7/3 – 7/7
- Pfizer Just Invested $25 million In This Biotech
- Cracks In The Labor Market? Not Yet, But They’re Coming
- Levi’s: Buy On The Dip Or Downtrend In Play?
- Who Wins And Who Loses With China’s Metal Restrictions
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
